DIAGNOSTICS INVESTORS

New Generation of Technologies Changing Treatment Paradigms

This panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:

  • Current areas of interest
  • Current challenges in this ecosystem – Navigating the competitive landscape
  • Commonly observed red flags
  • Successful deals

Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.

Panelists:

Request a Meeting

Scott Gazelle, Managing Partner, GreyBird Ventures (Moderator)

Scott Gazelle is a physician-scientist and academic entrepreneur who has been involved in the development, commercialization and assessment of new medical technologies for more than 25 years. He graduated from Dartmouth College and Case Western Reserve University Medical School. He trained in General Surgery and Radiology at University Hospitals of Cleveland, also serving as Chief Resident in Radiology, and then in Abdominal Imaging and Interventional Radiology at the Massachusetts General Hospital. In 1992 he joined the MGH faculty. In 1996, he received a Master’s Degree in Public Health, and in 1999, a PhD in Health Policy, both from Harvard University.

Scott has established and directed basic science, clinical and policy-focused research programs. As Associate Director of the MGH Center for Imaging and Pharmaceutical Development, his team developed contrast agents for CT and ultrasound. He also established and lead a multi-national team that developed and evaluated techniques for radiofrequency tumor ablation that have been used to treat thousands of patients. In 1997, Scott established the MGH Institute for Technology Assessment, now one of the largest and most successful academic programs for early-stage technology assessment and comparative effectiveness research.

Scott is currently Professor of Radiology at Harvard Medical School and Professor in the Department of Health Policy and Management at the Harvard School of Public Health. He is also Director of the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training, Vice Chair for Faculty Affairs and Associate Vice-Chair for Research in the MGH Department of Radiology. Scott has been President of the Association of University Radiologists, the Radiology Research Alliance, and the New England Roentgen Ray Society, Director of Partners Radiology, Chair of the American College of Radiology Commission on Research and Technology Assessment, Chair of the Radiological Society of North America (RSNA) Research Development Committee, and a member of the RSNA R&E Foundation Board of Trustees. He has authored more than 250 scientific articles, published three textbooks and presented numerous papers, lectures, and workshops nationally and internationally. Scott received a Gold Medal from the Association of University Radiologists, and was named “Outstanding Researcher” by the RSNA.

Scott serves on the Board of Hummingbird Diagnostics, Ceres Nanosciences, and Chair the Board of Atlas 5D.

Request a Meeting

George Li, Managing Partner, Proxima Ventures

Focus Areas:Medical Device and Diagnostic Mr. George Li has over 12 years experience of incubating, coaching and investing in life science industry. He is the managing partner of Proxima Venture capital fund which focus on investment in outstanding enterprises with disruptive medical technologies or service models that can address huge unmet medical needs. Proxima is managing two RMB funds and one USD fund. Proxima has invested 20+ innovative medical technology companies covering areas of cardiovascular, oncology, respiratory and diagnostic. In 2008, Mr. Li founded Biohub which is the leading life science accelerator/incubator in China. Biohub is running 5 incubators/accelerators with equipped central labs, CFDA cleared clean rooms in core cities of Wuhan, Hangzhou, Zhengzhou, Chengdu and Suzhou in China. Biohub has built an ecosystem including leading hospitals, public listed companies and network of seasoned entrepreneurs and can provide one stop professional services for start-up companies. Since it founded, Biohub has successfully incubated over 100 innovative life science projects covering pharmaceutical, biopharmaceutical, medical device, diagnostic and services. Before Biohub, Mr. Li co-founded Bioherms and brought the first HbA1c POCT diagnostic solution to China market. Mr. Li got his MBA from Hult International Business School and bachelor degree from Zhejiang University.

Request a Meeting

Sascha Berger, Partner, TVM Capital Life Science

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund.

Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea).

Prior to this recent role, Sascha successfully advised multiple renowned clients in corporate finance and strategy projects working as (senior) consultant for PricewaterhouseCoopers and the Boston Consulting Group. He was selected for the global leadership development program in his previous role and was named a global high-potential in PwC.

Sascha studied technology management in Munich, Singapore and Boston and holds a Master from Munich University of Technology with majors in entrepreneurial finance and chemistry, magna cum laude. In his master thesis he analyzed the specific challenges of biotech VC financing rounds. Later he completed his PhD studies in banking and finance while already working for PwC. He is a regular speaker on corporate finance topics for German universities and business schools.

During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.

Request a Meeting

Richard Kivel, Managing Director, GrayBella Capital

Richard Kivel serves as Managing Director of GrayBella Capital LLC., a VC/PE investment fund focused on biotech, healthcare and technology companies in Europe.

Richard has served as a CEO, Chairman and Board Director in both private and public companies in Europe, Russia, Singapore and the US. Previously, he was a Senior Manager at Bridgewater Associates, the world’s largest hedge fund, with $160 billion in global assets.

Richard is a guest lecturer on Global Entrepreneurship, Business Models and Venture Investing at MIT, Moscow School of Management Skolkovo and other universities in Europe and Singapore. He has many years of experience mentoring entrepreneurs in his role as Global Chairman of the MIT Enterprise Forum and Judge for the MIT $100K Entrepreneurship Competition. Richard also serves as a Trustee of the Bankinter Innovation Foundation, a global technology Think-Tank located in Spain and Portugal.

Request a Meeting

Martin Pfister, Senior Investment Manager: Life Sciences, High-Tech Gründerfonds

Dr. Martin Pfister joined the High-Tech Gründerfonds (HTGF) Medtech/LifeSciences team in Bonn in 2010. HTGF is the largest Seedfonds in Europe with about 900 Mio EUR under management and an active portfolio of about 260 technology-based portfolio companies, about 95 of which are in life sciences. studied a combination of Medicine and Pharmacy in Germany and New York University, Medical School with a PhD in Immunology Started his career in the hospital/laboratory moved to the start-up life sciences world 18 years ago. co-founded two companies in the molecular Dx field (VC backed, Exit) and healthcare services (privately owned, Exit 2018) @ HTGF manages a portfolio of 13 life science companies including Biotech, Medtech and digital health holds board member seat in 4 companies including clinical stage Biotech.